Bill Text: IL SB0771 | 2009-2010 | 96th General Assembly | Introduced

---

Bill Title: Amends the Illinois Public Aid Code. Makes a technical change in a Section concerning pharmacy payments under the Medicaid program.

Sponsorship: Partisan Bill (Democrat 1)

Status: (Introduced - Dead) 2009-08-15 - Pursuant to Senate Rule 3-9(b) / Referred to Assignments [SB0771 Detail]

Download: Illinois-2009-SB0771-Introduced.html

---

96TH GENERAL ASSEMBLY State of Illinois 2009 and 2010 SB0771 Introduced 2/6/2009, by Sen. John J. Cullerton SYNOPSIS AS INTRODUCED:
305 ILCS 5/5-5.12 from Ch. 23, par. 5-5.12
Amends the Illinois Public Aid Code. Makes a technical change in a Section concerning pharmacy payments under the Medicaid program.
LRB096 06838 DRJ 16924 b
A BILL FOR
SB0771 LRB096 06838 DRJ 16924 b
AN ACT concerning public aid.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Illinois Public Aid Code is amended by
changing Section 5-5.12 as follows:
(305 ILCS 5/5-5.12) (from Ch. 23, par. 5-5.12)
Sec. 5-5.12. Pharmacy payments.
(a) Every request submitted by a pharmacy for reimbursement
under this Article for prescription drugs provided to a
recipient of aid under this Article shall include the the name
of the prescriber or an acceptable identification number as
established by the Department.
(b) Pharmacies providing prescription drugs under this
Article shall be reimbursed at a rate which shall include a
professional dispensing fee as determined by the Illinois
Department, plus the current acquisition cost of the
prescription drug dispensed. The Illinois Department shall
update its information on the acquisition costs of all
prescription drugs no less frequently than every 30 days.
However, the Illinois Department may set the rate of
reimbursement for the acquisition cost, by rule, at a
percentage of the current average wholesale acquisition cost.
(c) (Blank).

SB0771 - 2 - LRB096 06838 DRJ 16924 b
(d) The Department shall not impose requirements for prior
approval based on a preferred drug list for anti-retroviral,
anti-hemophilic factor concentrates, or any atypical
antipsychotics, conventional antipsychotics, or
anticonvulsants used for the treatment of serious mental
illnesses until 30 days after it has conducted a study of the
impact of such requirements on patient care and submitted a
report to the Speaker of the House of Representatives and the
President of the Senate.
(Source: P.A. 93-106, eff. 7-8-03; 94-48, eff. 7-1-05.)